Results 111 to 120 of about 200,795 (317)
Which Patients With Dysfunctional Voiding Respond Well to Sacral Neuromodulation? ICI‐RS 2025
ABSTRACT Aims Dysfunctional voiding (DV) is characterised by fluctuating or intermittent urinary flow during voiding in neurologically normal individuals. Given the different definitions used and heterogeneous pathophysiologies, outcomes following sacral neuromodulation/sacral nerve stimulation (SNM/SNS) are variably reported.
Jalesh N. Panicker +8 more
wiley +1 more source
ABSTRACT Introduction Overactive bladder (OAB) is defined as urinary urgency, usually accompanied by increased daytime frequency and/or nocturia, with urgency urinary incontinence (OAB‐wet) or without (OAB‐dry), in the absence of urinary tract infection or other detectable disease.
John E. Speich +9 more
wiley +1 more source
Sex Difference in Sensitivity to α-Adrenergic Drugs in Blood Vessels of SHR Hindlimb
Yasumichi Hagino +3 more
openalex +2 more sources
Characterization of the Alpha-Kap FRET Biosensor to Determine Compartmentalized Beta-Adrenergic Receptor Camp Signaling in Distinct Intracellular Locations [PDF]
Michael W. Rudokas +5 more
openalex +1 more source
ABSTRACT Background The current literature summarizes the trends in the surgical management of stress urinary incontinence (SUI) and not the general trends of management for all UI types in the US. Additionally, recent evidence on racial and ethnic disparities in UI related surgical utilization is limited. Objective To describe the currently prescribed
Rawan O. Almadfaa +5 more
wiley +1 more source
A tethered ascorbate‐norepinephrine compound, 4‐UT, displays long‐acting adrenergic activity on rabbit aortic smooth muscle [PDF]
Robert Root‐Bernstein +2 more
openalex +1 more source
ASC‐1 transporter‐dependent amino acid uptake is required for the efficient thermogenic response of human adipocytes to adrenergic stimulation [PDF]
Rini Arianti +10 more
openalex +1 more source
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source

